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1. Introduction
Latest statistics based on GLOBOCAN 2008, the standard set of worldwide estimates of can‐
cer incidence and mortality produced by the International Agency for Research on Cancer
(IARC), revealed that prostate cancer (PC) is the most commonly diagnosed malignancy and
the second leading cause of cancer-related mortality in male in developed countries [1]. The
options in the treatment of PC are surgical tumor resection, hormonal therapy, radiothera‐
py, and adjuvant chemotherapy. These therapies, alone or in combination, show beneficial
effects and a significant curative rate in treating patients with localized PC in the early
stages. However, the development of locally advanced and/or metastatic hormone-refracto‐
ry prostate cancers (HRPCs) eventually results in disease recurrence. Most patients who un‐
dergo potentially curative resection for advanced and/or metastatic HRPCs subsequently
relapse due to the persistence of foci and micro-metastases. Therefore systemic chemothera‐
py may represent another option to eradicate the PC cells, including the highly tumorigenic
stem/ progenitor cells that can drive tumor growth at primary neoplasms and distant meta‐
static sites.
The existence of stem cells (SCs) was firstly demonstrated by James Till and the late Ernest
McCulloch in 1963 in their earlier work on the radiation sensitivity of mouse bone marrow
cells by showing that limited numbers of cells could give rise to clonal colonies of erythroid
and myeloid cells in the spleens of the irradiated hosts [2]. Although, much improvement
has been achieved in the development of methods to kill cancer cells that form a variety of
malignancies; nevertheless, relapse is an ongoing problem along with the development of
metastatic tumors at sites remote from that of the original tumor. One suggestion to account
for these phenomena is the existence of a stem cell with tumorigenic properties capable of
regenerating all the differentiated cell types presented in the original tumor. The key paper
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supporting the cancer stem cell (CSC) hypothesis from the laboratory of John Dick appeared
in 1997, in which they demonstrated that an isolated cell type was capable of initiating acute
myeloid leukemia (AML) [3]. With the knowledge provided by the science of stem cell biol‐
ogy, the Nobel Prize in Physiology or Medicine in the year 2007 was awarded jointly to Mar‐
io R. Capecchi, Sir Martin J. Evans and Oliver Smithies "for their discoveries of principles for
introducing specific gene modifications in mice by the use of embryonic stem cells".
Stem cells possess some unique properties: a) they are undifferentiated and unspecialized;
b) they are able to multiply for long periods while remaining undifferentiated (slowly cy‐
cling); c) they are capable of differentiating into specialized cells of a particular tissue (pro‐
duce progeny in at least two lineages); and d) they can be serially transplanted. The
combination of these properties is often referred to as “stemness” [4]. Stem cells can divide
symmetrically or asymmetrically. A symmetrical division occurs when two daughter cells
share the same stem cell features and happens when their numbers (stem cell pool) need to
be expanded, such as during embryonic development or after tissue injury. An asymmetri‐
cal division occurs when one of the progeny remains undifferentiated, thereby replenishing
the pool of SCs, while the other daughter cell can proliferate and differentiate into special‐
ized cells to generate new tissue mass.
Stem cells have long been implicated in prostate gland formation. The prostate undergoes
regression after androgen deprivation and regeneration after testosterone replacement. Re‐
generative  studies  suggested that  those  stem cells  are  found in  the  proximal  ducts  and
basal layer of the prostate. Many characteristics of PC also indicate that it originates from
stem cells. In this chapter, the biological and clinical implications of stem cells in prostat‐
ic carcinogenesis and the involvement of prostate cancer stem cells (PCSCs) in the many
faces of PC are demonstrated and summarized. The theory of a stem cell  origin of can‐
cers represents a major paradigm shift that may completely revamp to diagnosis, monitor‐
ing, and therapy of PC.
2. Prostate epithelium and stem cells
Human prostate is an exocrine gland that consists of basal, luminal and neuroendocrine cell
types embedded in a fibro-muscular stroma. The basal cells are relatively undifferentiated,
not dependent on androgens and hence express low levels of androgen receptors (ARs). Ad‐
ditionally, basal cells generate some secretory products such as CD44 [5], p63 [6], p27kip and
c-Met [7], cytokeratin 5 (CK 5) and CK 14 [8]. In contrast to the basal layer of cells, luminal
(or secretory) cells are terminally differentiated and specifically secrete the prostate like
prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) into the glandular me‐
dulla in response to androgens. Because, survival of these luminal cells depend on andro‐
gens they express ARs on a high level; whereas, their other specific secretory products are
CD57 [5], CK 8 and CK 18 [8]. The third type of cell in the cellular organization of the pros‐
tate epithelium is the neuroendocrine (NE) cell. The specific functions of NE cells have not
been deduced so far. However, Bonkhoff suggested that they are post-mitotic cells derived
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from luminal secretory cells [9]. NE cells are terminally differentiated, androgen insensitive
and scattered throughout the epithelium. Unlike the luminal cells, NE cells do not express
AR or PSA; but, they do express NE-specific markers such as chromogranin A and synapto‐
physin [10]. Basal and luminal cells can also be distinguished by comparing expression pro‐
files of other genes; like basal cells do mainly express CK 5 and CK 14, whereas luminal cells
express CK 8 and CK 18 [8]. Morphologically basal cells are small, flattened cells with con‐
densed chromatin and small amounts of cytoplasm. Luminal cells instead have increased cy‐
toplasm and their chromatin appear more opened [11]. Finally, the stroma is located under
the epithelial layer of prostate. Stromal cells are androgen responsive and they do express
AR. Development, maintenance and differentiation of epithelial cells are provided by these
stromal cells [12].
2.1. Prostate stem cells
Prostate stem cells (PSCs) need to carry following characteristics: they must be castration-
resistant, able to renew themselves and regenerate new tissue [13]. In contrast to the epithe‐
lial tissue of other adult organs, the prostate and mammary glands exert hormonal-
dependence. Therefore, to account for changes in hormone levels the PSCs should be
responsive to, but not dependent on, androgen for survival. This property is referred to as
castration-resistance. PSCs should have tissue-regenerative capacity to replenish the gland
after routine cell death. But, when compared to the hematopoietic stem cells that must gen‐
erate a vast array of mature lineages, PSCs only must regenerate a relatively simple double-
layered epithelium. Eventually, and most importantly, PSCs must be able to self-renew
meeting the needs of the organ over the course of a man’s lifetime.
2.2. Localization of stem cells within the prostate epithelium
In the 1980s, John Isaacs and colleagues performed classic androgen cycling experiments
and suggested that prostate epithelium must contain a SC population. Than, when rodents
are deprived of androgen by surgical or medical castration, the gland atrophies due to apop‐
tosis of terminally differentiated cells which are dependent on androgen for their survival
[14]. However, when androgen is replaced the gland regenerates and resumes its normal
functions. This involution and regeneration can be repeated for many sequential cycles. The
regenerative capacity has been attributed to a population of long lived SCs within adult
prostate epithelium that are thought not androgen-dependent for survival, but androgen-
sensitive and androgen-responsive. Apoptosis occurs mostly in androgen-dependent lumi‐
nal cell epithelium, while the androgen-independent basal cells generally remain unaffected
[15]. In accordance with this, the regenerative capacity is referred to the action of basal SCs,
while the harbor of these self-renewing cells is confined to the basal-cell layer [14, 16]. Later,
also other observations and studies have supported this hypothesis in many ways; like, that
basal cells exhibit a higher proliferation rate in normal and hyperplastic acini than luminal
epithelial cells [9]. Or for example, as bromodeoxyuridine (BrdU) labeling studies have sug‐
gested that prostatic tumor-initiating cells reside in the basal cell compartment and express
a p63+ signature [17]. And, that basal cells preferentially survive after androgen ablation;
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whereas, 90% of luminal epithelial cells are lost through programmed cell death [18]. An‐
drogen treatment restores the secretory glandular structure, hinting towards that the basal
compartment contains SCs that undergo transit amplification to repopulate the luminal epi‐
thelium [19]. Cell types expressing an intermediate phenotype of basal and luminal cell
characteristics have been identified in the developing and adult prostate [19].
On the other hand, there are also some studies that do not support the idea that SCs reside
in the basal cell compartment. Experiments in mice where SCs were labeled with BrdU, sug‐
gested that stem cells are not restricted to the basal cell compartment; but, may also reside in
luminal cell layer as a slow proliferating population in the proximal part of prostatic ducts
[20]. Using tissue rescue experiments, Gerald R. Cunha and colleagues have demonstrated
that the embryonic p63 null urogenital sinus developed into prostate when engrafted under
the renal capsule of male mice [21]. Although, basal cells were absent the grafts contained
luminal and NE cells, demonstrating that p63 was essential for basal but not for luminal and
NE cell differentiation [21].
In human prostate, there is a consistent body of evidence that the SCs reside in the basal
layer. Within the basal layer, CD133+/α2β1hi  (high expression of α2β1  integrin) cells repre‐
sent a small subpopulation of quiescent cells with SC characteristics: they have a high pro‐
liferative potential in vitro and can reconstruct functional prostate acinar structures in vivo
[22].  Molecular  characterization  of  these  cells  revealed  that  they  do  not  express  AR  at
mRNA level [23], indicating that they are not dependent on androgen for their survival.
Using CD49f and tumor-associated calcium signal transducer-2 (TROP2) as markers, Gold‐
stein and collaborators identified basal cells with enhanced sphere-forming and tissue re‐
generating abilities [24].
2.3. Characterization of prostatic stem cells
Recent studies have revealed that a very small subpopulation of multipotent and undiffer‐
entiated PSCs, comprising about 0.1–3.0% of the total prostatic epithelial cell population,
principally reside within specialized areas or “niches” localized in the basal cell layer of aci‐
nar and ductal regions of the human prostate gland [5]. Anne T. Collins and colleagues iso‐
lated and characterized human adult SCs based on the identity of cell surface integrin
antigens [25]. They showed that, in vivo, putative SCs express higher levels of the α2-integrin
subunit than other cells within the basal layer. Later, it was shown that a subpopulation of
α2β1hi basal cells express the CD133 antigen and that this expression correlates with a high
proliferative potential and ability to regenerate a fully differentiated prostatic epithelium
with expression of prostatic secretory products in vivo [22]. CD133+ cells possess three im‐
portant attributes of epithelial stem cells: they are rare, comprise a high in vitro proliferative
potential, and are capable of reconstituting highly branched ductal structures. Besides, Patri‐
cia E. Burger and colleagues reported that SCs can be purified from isolated proximal duct
regions by virtue of their high expression of the cell surface protein stem cell antigen 1
(SCA-1) [26]. Subsequently, it was demonstrated that the Sca-1 surface antigen can be used
to enrich for murine prostate cells displaying multiple properties of primitive cells including
androgen independence, replication quiescence, multi lineage differentiation, and in vivo
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prostate regenerative capacity [27]. Combined cell surface markers such as
CD45−CD31−Ter119−Sca-1+CD49f+ were defined by Devon A. Lawson and colleagues who
found that prostate cells can self-renew to form spheres for many generations and can differ‐
entiate to produce prostatic tubule structures containing both basal and luminal cells in vivo.
These cells also localize to the putative PSC niche in the proximal region of the prostate
gland [28].
2.4. Prostate stem cell niche
In all epithelial organs, adult SCs are maintained in a tissue niche that regulates stem cell
fate decisions. The niche provides structural support, as well as the biological cues that in‐
fluence the SCs’ decision to self-renew or divide into more differentiated progeny. Integrin
and junctional proteins play a major role in regulating SC differentiation in the prostate [29].
For instance, integrin α6 shows a wider distribution amongst SC populations in the prostate
tissue [28]. It was also shown that the high surface expression of α2β1 integrin in human
prostate epithelium correlates with colony forming ability and the potential to regenerate a
fully differentiated prostate epithelium in vivo [25]. Additionally, proteins belonging to the
connexin, cadherin and catenin families were reported as key molecules mediating cell-cell
and cell-extracellular matrix interaction that dictate cell differentiation decisions [30].
Prostate homeostasis is maintained as a result of androgenic regulation of stromal epithelial
interactions. Mesenchyme is the key androgen target tissue during development of prostate
and many androgenic effects expressed in epithelium are elucidated trough paracrine influ‐
ences from the mesenchyme [31].
The pathways controlling SC fate in prostate include NOTCH1 and Transforming growth
factor beta-1 (TGFβ1) signaling. NOTCH signaling is critical for normal cell proliferation
and differentiation in the prostate, and deregulation of this pathway may facilitate prostatic
oncogenesis [32]. Increased TGFβ1 signaling has been found in the quiescent proximal re‐
gion of the ducts in an androgen-replete animal and cells in this region were also overex‐
pressing the B-cell leukemia/lymphoma-2 (Bcl-2) protein, which protects them from
apoptosis [33]. This signaling seems to be responsible for a quiescent stem cell niche.
3. Cancer stem cells
The cancer stem cell (CSC) theory has started more than a century ago with the “embryonal
rest hypothesis” that was relying on histological similarities between teratocarcinomas and
embryonic tissue [34] and later was than accelerated by findings that leukemia could be
transferred by a single cell in a mouse model system [35]. Later investigations clarified that
when this single cell was transplanted to non-severe combined immunodeficiency (SCID)
mice it could induce leukemia that was phenotypically identical to the parental tumor lead‐
ing to the conclusion that a leukemic tumor stem cell had developed from hematopoietic
stem cells [3]. The first CSCs in a solid tumor was discovered for breast cancer in the year
2003 [36]. Following that, CSCs were also found in solid tumors like liver, lung, thyroid,
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skin, pancreas, colon and prostate cancer [37]. Nevertheless, through the 1960s transplant
experiments had proven that cancers were composed of heterogeneous cell populations
with some differences in their self-renewal capability and potential for reconstituting a tu‐
mor following transplantation [38-40]. These early investigations made the researchers think
that the actual tumor cell population could be arisen from a small group of CSCs and two
theories were suggested upon this idea [39]. In the stochastic theory, every cell in a tumor
population is believed to be a potentially tumor initiating cell; but, each cell’s possibility of
entering the cell cycle is low and controlled stochastically. Whereas, the hierarchy theory as‐
sumes that the tumor is functionally heterogeneous and only a small subpopulation of cells
in it have the ability to initiate tumor growth [40]. Regardless of the theories, CSC is general‐
ly accepted as the original cell of a tumor that generates an accumulation of self-sustaining
cells with unlimited self-renewal capability. Meaning it is that one cell that later raises the
formation of a heterogeneous bulk tumor which differentiates, comprises metastatic ability,
preserves itself by activating anti-apoptotic pathways, and is responsible of tumor relapse.
In this context, the self-renewal capability is very important to SCs; i.e. the one or both
daughter cells -that result after cell division- that keep the ability to replicate and form the
same differentiated cell lineage as the parental cell. CSCs have the capability of creating the
generations of a constantly growing tumor and can either arise from the stem cells of a cor‐
responding tissue or from mutation bearing tissue cells that dedifferentiate to become can‐
cerous SCs [41].
3.1. Cell division in cancer stem cells
Stem cells can divide symmetrically or asymmetrically: while the symmetric division results
in two new SCs; asymmetric division gives rise to a new stem cell and a daughter cell that
undergoes a differentiation process. Stem cells alternate between these two division types.
Asymmetric cell division is regulated by some intrinsic factors such as the specific arrange‐
ment of cell polarity and/or cell fate factors like Numb or PAR-aPKC, and by extrinsic mech‐
anism like the stem cell niche. Thus, asymmetric division is not necessary for stem-cell
identity but rather is a tool that stem cells can use to maintain appropriate numbers of prog‐
eny. The facultative use of symmetric or asymmetric divisions by stem cells may be a key
adaptation that is crucial for adult regenerative capacity [42]. The result of each division is
different; since symmetric cell division gives rise to induce new tumors, the machinery that
promotes asymmetric cell divisions has an evolutionarily conserved role in tumor suppres‐
sion [43, 44].
3.2. Regulatory mechanisms of CSCs
Regulatory proteins and pathways establish a balance between a CSC’s self-renewal ability
and its death by apoptosis. The WNT, SHH, NOTCH, and PI3K/AKT/mTOR signaling path‐
ways are especially important in this regulation and are often found be impaired in tumors.
The WNT signaling pathway is mainly involved in cell proliferation and differentiation. A
mutation in one of its components resulting either in an up-regulation or disruption of the
signaling cascade can accelerate tumorigenesis; dysregulation of the WNT pathway compo‐
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nent E-cadherin can also lead to metastasis [45, 46]. Differentiation and self-renewal of adult
SCs is usually controlled by the SHH pathway and disruption of it results in their aberrant
differentiation and proliferation [47]. The NOTCH signaling pathway also regulates the dif‐
ferentiation, proliferation and self-renewal of adult SCs. Dysregulation of this pathway af‐
fects specific tissues and often leads to basal cell carcinoma, breast-, kidney- and prostate
cancer [48-50]. In mouse models a significant inhibition of tumor growth could be achieved
when the NOTCH signaling cascade was blocked [51]. The PTEN, a tumor suppressor pro‐
tein with function in cell cycle regulation, is acting on the PI3K/AKT/mTOR signaling path‐
way. Inactivating mutations of PTEN can cause uncontrolled growth and cell division and
are often found in tumors such as brain, bladder, prostate and kidney cancers [52-54].
3.3. Therapeutic approaches to target CSCs
Searching for powerful therapeutic approaches that specifically target CSCs is an accelerat‐
ing area of research, after the discovery that CSCs significantly influence metastatic diseases
and drug resistance. For instance, relapse is a result of a small CSCs population’s survival
which has self-renewal ability. If these CSCs are not exterminated by chemotherapy or tar‐
geted disruption of the SHH or NOTCH signaling pathways, they stay dormant in the target
organs or bone marrow until triggered to regenerate the heterogeneous cell populations of a
tumor [55]. But, attention should be focused on whether all solid tumors are sustained by
CSCs and whether cell surface specific markers could be found that differentiate between
normal SCs and CSCs. A great improvement will be achieved in cancer therapy when CSCs
are selectively eliminated, while normal SCs are spared and thus left unaffected. Identifica‐
tion of a specific CSC marker in cancer of interest would simplify the development of anti-
cancer drugs that eliminate the CSCs from the tumor cell population [56].
4. Prostate cancer stem cells
4.1. Origin of PCSCs
The origin of PCSCs continues to stay as a controversial issue. Different cells in origin may
generate clinically relevant subtypes with different prognosis and outcome. There are two
possible cell origin resources in PC: the basal and luminal cell-of-origin.
4.1.1. Basal cell-of-origin
Much stronger studies came from several independent laboratories that used different PC
models to support the view that basal stem cells provide the cell-of-origin for PC. When
CD49fhiTrop2hi cells were selected from the basal fraction, transfected with Akt/Erg vectors
and transplanted to induce initiation of prostatic intraepithelial neoplasia [57]; these basal
cells derived from primary benign human prostate tissue initiated PC in immunodeficient
mice [24]. It was also reported that Lin-Sca-1+CD49fhi cells isolated from the basal fraction of
murine prostate produced luminal-like disease characteristics of human PC after transplan‐
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tation [58]. Recently, Norman J. Maitland and colleagues reported that selected cells with
basal phenotypes are tumor initiating and basal SCs are the source of a luminal progeny
[23]. In addition, a small population of TRA-1-60+ CD151+ CD166+ tumor initiating cells
(TICs) isolated from human prostate xenograft tumors exhibited stem-like cell characteris‐
tics and recapitulated the cellular hierarchy of the original tumor in serial xenotransplanta‐
tion experiments [59]. Moreover, these cells expressed basal cell markers and showed
increased Nuclear factor-κB (NF-ĸΒ) signaling.
4.1.2. Luminal cell-of-origin
Luminal cells are believed to be the cells of origin for human PC, because the disease is char‐
acterized by AR+ luminal cell expansion. That is why pathologists diagnose PC based on the
absence of basal cell markers. It is known, that rare luminal cells which express the homeo‐
box gene Nkx3.1 in the absence of testicular androgens (castration-resistant Nkx3.1-express‐
ing cells, CARNs) are bipotential with self-renewal capability in vivo [60]. Single-cell
transplantation of CARNs can reconstitute prostate ducts in renal grafts. Besides, targeted
deletion of PTEN in CARNs results in rapid formation of carcinoma following androgen-
mediated regeneration. Hanneke Korsten and colleagues [61] showed that genetic altera‐
tions are first seen in a subset of luminal cells expressing the progenitor markers TROP2 and
SCA-1, implying that the luminal cells are the cell-of-origin in this model.
The reason why the origin of PC and the cell type of origin remains a controversial issue is
in part of the distinct functional assays that were employed. Furthermore, since PC is a very
heterogeneous disease it is plausible that different PCs are derived from different originat‐
ing cell types.
4.2. Characterization and markers of PCSCs
Every stem cell does not express the defined markers that are used to isolate SCs from various
cancerous or normal tissues. Although the CD133, CD44, SCA1 and THY1 cell surface mark‐
ers are commonly used to enrich CSCs; they are also expressed in normal stem cells as well as
in many non-stem cells in various tumors and tissues. Eventually, the majority of cells ex‐
pressing these markers are not SCs. Apart from that, a marker that is found to be functional in
identifying a SC from one tissue may not be useful for identifying the SC in another tissue.
Another feasible way of identifying SCs, besides searching for specific cell surface markers, is
by label retention (BrdU incorporation) assays [62]. This DNA labeling assay depends on the
label retaining characteristics of the seldom dividing SCs [63]. Finally, CSCs can be isolated by
the detection of a “side population (SP)” of cells that actively transport lipophilic dyes out of
the cells by drug-transporting proteins [64]. Margaret A. Goodell and colleagues first ob‐
served that a small population of bone marrow-derived cells that were incubated with the lip‐
ophilic dye Hoechst 33342 failed to accumulate an appreciable amount of this dye [65]. This
subpopulation  was  identified  by  dual-wavelength  flow  cytometry  analysis  as  the
HoechstlowSP. Remarkably, the SP was highly enriched for hematopoietic stem cells. Subse‐
quently, the SP technique was widely employed to enrich stem-like cells from solid cancers.
This technique was also used for PC cells and the SP of cells derivable from this primary pros‐
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tate tumors was ∼1% [66]. Since the gold standard to confirm CSCs is in vivo tumor develop‐
ment, analyzed and sorted SP cells were inoculated into immune-deficient mice and tested for
tumor producing ability. By this, it was found out that cell surface markers combined with SP
analysis are a more accurate way in identifying the real SC population.
The density of CSCs in a tumor is probably less than 0.1% [37]. Therefore, to obtain a good
yield after isolation these cells certainly should be specified first. So far, identification can be
achieved via characteristic cell surface markers, DNA labeling, and the cells’ ability to expel
dyes. Table 1 presents the expression profiles of cell surface proteins that are specific for SCs
or tumors. But, it should kept in mind, that many cell surface proteins are not too specific to
CSCs, because they are also expressed on physiological stem cells; and thus, using antibod‐
ies to detect them can lead to false-positive results due to non-specific cross reactivity.
Tumor type Cancer stem cell marker
Acute myeloid leukemia CD34/CD38
Breast carcinoma CD44/CD24-/ALDH
Bladder carcinoma Side Population [67]
Colorectal carcinoma CD133, CD44, EPCM, ALDH
Ewing’s sarcoma CD133
Gastric carcinoma CD44
Medulloblastoma, Glioma CD133
Pancreatic carcinoma CD133, CD44, CD24, ALDH, EPCM
Prostate carcinoma CD133, CD44, ALDH
Hepatocellular carcinoma CD133, CD44, ALDH
Lung carcinomas (non-small cell and small cell) CD133, Side Population [67], ALDH
Head and neck carcinoma CD44, Side Population [67], ALDH
Endometrial carcinoma CD133, Side Population [67]
Table 1. Established CSC markers expressed in tumors of different tissues in human [56]
4.3. Methods for assaying PCSCs
Although, a SC in any type of adult tissue has the common self-renewal and differentiation
abilities, it will be wrong to generalize the results obtained from one tissue while defining a
SC in another tissue. SCs in different tissues can differ significantly from one another. The
actual assay to identify a CSC that has self-renewal and tumor progression capability is an in
vivo model known as the serial transplantation in animal models. Other assays are usually
generated in an in vitro environment and to be ideal, they have to full-fill the following crite‐
ria: they should be quantitative, highly specific in measuring only the cells of interest, suffi‐
ciently sensitive to measure candidate stem cells even at low frequencies, and fast [37].
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For SC studies, human primary cells are the optimal tools to mimic and represent the origi‐
nal characteristics of tissues; however, it is quite difficult to get primary cell cultures from
PC tissues due to limited access. Furthermore, cell lines can serve as a resource for CSC
studies, but there are several disadvantages in utilization of this in vitro model: it cannot rep‐
licate exact in vivo conditions during the long-term culture process and some cell property
changes might take place like gene alterations; the in vitro cultured cells often lose their orig‐
inal differentiated function; and it cannot stably maintain the exact properties of the original
organ. Nevertheless, primary PC cells, established PC cell lines, xenograft and animal mod‐
els have all been utilized to identify PCSCs with different surface markers.
4.3.1. In vivo systems
Gerald R. Cunha and Ben Lung have developed tissue recombination of a rodent model for
the growth of normal epithelial cells in 1978 [68]. In this system, tissue fragments of fetal ur‐
ogenital sinus mesenchyme were used to support the growth of normal prostate epithelial
tissue fragments when implanted in collagen under the renal capsule of immunodeficient
mice. This system was later modified to evaluate the growth activities of different prostate
cell subpopulations using mechanical and enzymatic digestion to dissociate both, the uro‐
genital sinus mesenchyme and adult murine prostate tissue into single cell suspensions [69].
Dissociated prostate epithelia regenerate ductal structures that histologically resemble nor‐
mal murine prostate. Matrigel transplantation method was described that provides a recon‐
stitution assay of prostatic cells. It was shown that the prostate contains stem cells capable of
reconstituting the whole prostate and this method can be used to analyze prostate stem
cells, epithelial mesenchymal interactions, and prostate cancer stem cells [70]. Ken Goto and
colleagues performed serial transplantation that was analogous to the serial reconstitution
method to investigate PSCs self-renewal [71]. They showed that regenerated prostate tissue
could be dissociated and transplanted to regenerate prostate tissue at least three times.
4.3.2. In vitro culture systems and assays
There are two types of culture system to study CSCs: primary cell cultures and cell lines.
Primary cell cultures are directly established from human tissues and have the advantage
that their cells represent the original features of the tissue. However, difficulties including
the limited access to biopsy materials, the need for the exclusion of contamination by cancer
or normal cells, their limited lifespan, and the small population of the putative SCs are its
disadvantages [72]. Cell lines are permanent cell cultures with unlimited proliferation ca‐
pacity. They are widely used in many aspects of research as the most common in vitro cul‐
ture model, because they have a big advantage in being easy to handle for their infinite
reproducible quantities. So far, most of the human PC cell lines have been established from
metastatic lesions or from xenograft tumors.
Prostate colony assay: The clonal and population analyses of mammalian stem cells was first
accomplished by using two dimensional culture conditions [73]. Co-culture with irradiated
fibroblast feeder layer is now also used to cultivate human prostate epithelial cells. In this
assay, the feeder layer contains serum free medium (but, growth factors added) and low cal‐
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cium [74]. Under these conditions, murine prostate epithelial cells form colonies of cells that
express epithelial cytokeratins when cultured with irradiated 3T3 feeder cells [28].
Prostate sphere assay: Colonies that are derived from primitive cells cannot be passaged effi‐
ciently, since culture conditions promote cell differentiation. The three dimensional sphere
is a non-adherent culture system that has been used as a useful model to elucidate stem cell
characteristics [75]. A suspension culture system like this is thought to keep cancer stem
cells in their undifferentiated state facilitating their enrichment; like for AR-negative and
AR-positive PC cell lines that both can form prostaspheres [76]. Actually, all PC cell lines
can form prostaspheres; but, because heterogeneity exists only a subpopulation of cells in
each cell line can form these prostaspheres. The expression of stem cell markers, such as
CD133 and CD44, is also significantly enhanced in a prostasphere.
In contrast to the suspension sphere culture systems 3-D culture in Matrigel, which is a
widely used commercially available basement membrane, has been demonstrated to pro‐
mote the differentiation of PSCs. It was possible to induce morphological and phenotypical
differentiation in normal and malignant prostate epithelial cell lines with Matrigel [72].
4.4. Alterations in signaling pathways of PCSCs
Alterations in the signaling pathways are probably one of the reasons why cancer stem cells
gain a tumorigenic potential. Thus, disclosing the signaling pathways’ expressional regula‐
tions might provide potential therapeutic targets. The WNT, JAK/STAT, NF-ĸΒ, NOTCH,
and PI3K/AKT/mTOR signaling pathways were found to be the regulators of CSC biology in
prostate tissue and therefore are candidate targets. The idea of inhibiting signaling that in‐
duces proliferation and survival could mean an effective therapy for PC [77].
Proteins acting in the WNT signaling pathway are usually over-expressed in PCSCs. Hence,
tumorigenesis is promoted and prostaspheres which have self-renewal capacity exhibit pro‐
liferation, differentiation, and heterogeneous expression of stem cell-associated markers
such as CD44, ABCG2 and CD133. When WNT inhibitors are applied the size of prosta‐
spheres and their self-renewal ability can be reduced; plus, the CD133 and CD44 expressions
are down-regulated. WNT activity also regulates the self-renewal capacity of PC cells that
have stem cell-like features and inhibition of WNT signaling potentially reduces the self-re‐
newal ability of PCSCs with an enviable therapeutic outcome [76].
The JAK/STAT signaling pathway seems to be important in PCSC biology. Than, when
PCSCs expressing aldehyde dehydrogenase (ALDH+), which is involved in the formation of
bone metastasis, were treated via a galiellactone- a specific STAT3 signaling inhibitor-; apop‐
tosis of cancerous cells could be induced [78]. Besides, in vivo targeting of STAT3 in a drug
treated DU145 xenograft gave also desired results. Therefore, targeting of JAK/STAT signal‐
ing pathway components might be a promising therapeutic resulting in ALDH1A1 expres‐
sional down-regulation in PSCSs [78]. The importance of the NF-ĸΒ signaling pathway came
up after the finding of enhanced functional signaling in purified naïve stem-like human pro‐
static TICs. When cells were treated with small molecular inhibitors that targeted the NF-κB
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signaling pathway secondary sphere formation in vitro and tumor-initiation in vivo could be
inhibited [59].
Cell fate specification, initiation of differentiation, and SC maintenance is regulated by the
NOTCH signaling pathway in many tissues [79]. The over-expression of various proteins
that function in the NOTCH signaling cascade has been found in a number of different tu‐
mors including PC. For example JAGGED-1, a NOTCH receptor ligand, has been found to
be significantly more expressed in metastatic PC when compared with localized PC or be‐
nign prostatic tissue samples. This up-regulation also correlated with clinical features like
recurrence, progression and metastasis of PC [80]. When Jagged-1 expression was down-
regulated with small interfering RNAs (siRNAs) cell growth was inhibited and cell cycle ar‐
rest achieved in the S phase of cell division [81].
The PI3K/AKT/mTOR signaling pathway member PTEN was first identified as a candidate
tumor suppressor gene that was frequently mutated in brain, breast, and prostate tumors
[82]. Introduction of PTEN into cancer cells that lack PTEN function down-regulated cell mi‐
gration and survival, and induced cell cycle arrest and apoptosis [82]. PTEN is the most mu‐
tated gene in metastatic PC that is advanced and has an aggressive tumor phenotype; and
has been associated with cancer progression in 30–60% of PC cases [83]. An association be‐
tween androgen-independent tumor growth and PTEN mutations has also been discovered
[84]. A number of mouse models for PC suggested that PTEN might play a role in the initia‐
tion or early progression of this disease. PTEN heterozygous mice are likely to develop epi‐
thelial dysplasia and hyperplasia resembling high-grade PIN and adenocarcinoma [53, 85].
While PTEN mutations lead to a predisposition for PC in mouse models, such an association
could not be shown for human yet [83, 84].
4.5. Endocrine effects on PCSCs
In PC, the stromal niche or microenvironment plays a critical role in regulating differentia‐
tion of CSCs, probably by altered endocrine and/or paracrine signaling. Direct androgen
binding to epithelial ARs is not required for epithelial differentiation, but is essential for the
induction and maintenance of a secretory activity [11].
AR is a member of the steroid hormone receptor family and its over-expression is involved
prostate tumorigenesis. Consequently, androgen deprivation therapy (ADT) has been used
to treat locally advanced and metastatic PC [86]. Despite initial regression of the tumor the
majority of patients inevitably develop castrate-resistant prostate cancer (CRPC), which es‐
tablishes metastases relatively rapidly and is subsequently incurable by current treatment
strategies. Mouse model studies revealed that androgen ablation can select for more aggres‐
sive and metastatic disease, which means that current hormonal therapies do not affect the
AR--CSCs [87]. ADT may promote disease progression by causing an increase in the cas‐
trate-resistant SC pool and/or activating quiescent SCs to repopulate the tumor with andro‐
gen-independent SCs. Vander et al. reported that unlike normal adult human prostate SCs,
CD133+ PCSCs are AR+ and suggested that AR+ prostate TICs are derived from a malignant‐
ly transformed intermediate cell that acquired “stem-like activity”. The AR signaling path‐
way might therefore comprise another therapeutic target, especially for prostate TICs [88].
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In addition to androgens, estrogens play key roles in prostate carcinogenesis and progres‐
sion. However, the mechanisms are not fully understood. Although there is still no direct
evidence that estrogens initiate PC in humans, there is accumulating evidence pointing to‐
wards a central role for estrogens in PC [89]. To give just some examples are the rising E2:T
ratio in aging men, association of estrogen metabolizing gene polymorphisms and elevated
urine hydroxy-estrone ratios with higher PC risk, progressive increase in aromatase expres‐
sion in PCs upon advancement to metastatic disease, and marked alterations in estrogen re‐
ceptor expression with cancer progression. Normal human prostate progenitor cells are
responsive to estrogens with increased rates of self-renewal, implicating them as direct es‐
trogen targets.
The importance of estrogen receptor (ER) expression, e.g. ERα and ERβ, is unknown; but, is
of interest based on the integral role of estrogens in prostate carcinogenesis. The expression
of ERα is low and hard to detect in prostatic epithelial cells, where ERβ is predominantly
expressed. An ERβ agonist compound could selectively induce apoptosis in castrate-resist‐
ant CD133+ basal cells, providing a rationale for further exploring the role of ERβ in PC and
PCSCs [90].
Prolactin (PRL) is a peptide hormone that is secreted by the pituitary gland. It regulates sev‐
eral physiological functions, many of which relate to male and female reproduction. In hu‐
mans PRL is also produced by prostate epithelial cells under normal physiological
conditions. Local PRL profoundly affects the prostate epithelial compartment, with dramatic
expansion of basal and stem-like epithelial cells, markedly enhanced epithelial cell prolifera‐
tion, and strong activation of the STAT5 pathway as three hallmarks of tumorigenesis [91].
4.6. Potential role of PCSCs in metastasis
PC is the second leading cause of cancer death in male; but, because of the progress made in
the diagnosis and treatment of primary PC, mortality in 70 - 80% of the patients is increas‐
ingly linked to its metastatic disease. The bone marrow is the most frequent site for metasta‐
sis in PC; and stem cells, besides their role in tumorigenicity, are highly migratory cells that
are involved in bone metastasis formation [92].
CSCs contain a subpopulation of cells that are exclusively capable of disseminating and sub‐
sequently providing the substrate for tumor metastasis; e.g. CD44+ PC cells are more tumori‐
genic and metastatic than the corresponding CD44- cells [93]. Stromal cell derived factor and
its C-X-C chemokine receptor type 4 (CXCR4) form a critical regulatory axis for SC migra‐
tion, engraftment and homing, and also function in the metastasis of breast and prostate
cancer [94]. Using a mouse/human comparative translational genomics approach an 11-gene
signature that consistently displays a stem cell–like expression pattern in metastatic lesions
of prostate carcinomas could be recovered from multiple distant target organs [95].
On the other hand, some incidents do not support the CSC involvement in metastasis. For
example, CD44+CD24- and CD44+CD24+ breast CSCs have same metastatic potential [96].
Then, in an orthotopic pancreatic cancer model CD133+ cells were not metastatic, whereas
CD133+CXCR4+ cells showed strong metastasis [97]. Also, CD133- colon cancer cells were
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more aggressive and metastatic than their CD133+ counterparts [98]. In conclusion, metasta‐
sis and tumor initiation might be processed by distinct cancer cell populations, probably by
metastatic CSCs.
Tumor microenvironment facilitates cancer metastasis by several mechanisms. When hu‐
man PC cells were injected into the dorsal prostate of a nude mouse more metastasis was
generated, than when cells were injected subcutaneous [99]. Later, it was shown that dorsal
prostate-implanted human PC cells over-express many CSC genes including osteoponin,
CXCR4, CD133, ABCG2, CD44 and CD24. Some of these genes clearly have functional roles
in PC metastasis [100]. But, the exact molecular mechanisms that account for the microenvir‐
onment regulated PC cell metastasis are still not known.
4.7. MicroRNA-mediated regulation of PCSCs
For the identification of novel PC therapeutic targets it is important to evaluate functional
genes that are related with CSCs self-renewal and survival abilities. The experiences with
PC therapy showed that PC recurs frequently; meaning that chemotherapy, radiotherapy,
androgen-ablation therapy, and radical prostatectomy are not sufficient enough to eliminate
TICs or metastatic cells. PCSCs are androgen independent and therapy resistant cells. Thus,
generating novel therapies that specifically target PCSCs may be more effective than those
that target differentiated PC cells. New approaches depend on CSC exterminating rather
than total tumor decay. The limitation for these studies is to be able to specifically target
CSCs in normal tissue that also contains its specific SCs; since, they have similar expression‐
al and antigenic profiles [101]. Consequently, new markers are needed to distinguish CSCs
from tissue specific SCs. microRNAs (miRNA) can be considered as such novel therapeutic
target molecules for distinguishing PCSCs from normal SCs. MicroRNAs are 21- to 25-nu‐
cleotide (nt)–long, noncoding RNAs that induce the target mRNA degradation or repress
mRNA translation by imperfect binding to their 3'-untranslated region (UTR) [102].
Depending on their expressional profiles and their target-mRNA types miRNAs can be divid‐
ed into two classes: one that act like oncogenes (oncomiRs) and the other that act like tumor
suppressor genes. OncomiRs are commonly up-regulated in tumors and target tumor suppres‐
sor mRNA transcripts, causing a decrease of tumor suppressor protein syntheses and thus
function. Tumor suppressor miRNAs on the other hand are mostly down-regulated in tumors
and therefore cannot target and inhibit the syntheses of the specific oncogene mRNA tran‐
scripts  into  oncoproteins.  When tumor  suppressor  miRNAs are  experimentally  over-ex‐
pressed in cancer cells they inhibit their proliferation, invasion and proliferation capacity [103].
Expression profiling of miRNAs in PC have showed that some miRNAs were significantly
up- or down-regulated when compared to normal prostate tissue, pointing to the impor‐
tance of miRNAs in tumor progression and pathogenesis; e.g. miR-34a and miR-34c were
found to have an important role in AR-dependent and p53-mediated apoptosis [104, 105].
miR-125b was an up-regulated miRNA in clinical PC samples and androgen independent
cell lines; thus, its up-regulation might be related with androgen-independence and survival
[103]. Another up-regulated miRNA in PC was miR-21; but, it affected tumorigenesis, inva‐
sion and metastasis by inhibiting the synthesis of proteins that normally function in these
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pathways. miR-21 also inhibits apoptosis [103]; and, contributes to drug resistance of PC to
docetaxel treatment [106, 107]. miR-148a was defined as an androgen-responsive microRNA
that promoted growth when up-regulated in the PC cell line LNCaP and one if its mRNA
targets was found to be the cullin associated and neddylation-dissociated 1 (CAND1) tran‐
script, coding for a tumor suppressor protein [108].
In contrast, miRNAs like miR-15a and miR-16-1 were found to be down-regulated in PC; their
over-expression achieved by intra-cell delivery methods showed significant tumor regression
capacity in vivo [103]. Other down-regulated miRNAs with tumor suppressor function in PC
were miR-125b, miR-99a, miR-99b and miR-100. Again, when their expressions were restored,
PSA expressions could be reduced and PC cell proliferation was inhibited [109].
miR-145 and miR-143 are tumor suppressor miRNAs that are commonly dysregulated in all
cancer types. miR-145 and miR143 are also first transcribed together on a cluster and cleaved
off during the miRNA maturation process. In PC miR-145 is down-regulated and over-ex‐
pression of it has an anti-tumorigenic effect, resulting with the inhibition of migration and
invasion of PC cells [103].
Some miRNAs take part in formation of androgen-independent PC; and, by comparing an‐
drogen-dependent and -independent PC samples, miR-146a has been revealed as such [110].
Finally, an example of a miRNA that is regulated by its target is miR-34a. The tumor sup‐
pressor and transcription factor p53 directly regulates the expression of miR-34a, which is
decreased in CD44+ PC cells. When normally expressed it could inhibit PC regeneration and
metastasis by directly repressing CD44 [111, 112]. The list of miRNAs which expressions are
most significantly altered in PC are given in Table 2.
4.8. New therapeutic approaches in targeting PCSCs
Despite progress in the therapeutic approaches that significantly increased the survival rate
of PC patients, most prostate aggressive tumors become resistant to currently used treat‐
ment protocols. PC that initially responded well to a standard chemotherapy often recur
with selective outgrowth of tumor cell subpopulations and get resistant not only to the orig‐
inal chemotherapeutic agent but also to other therapeutics. Thus, for most patients with re‐
lapse of castration-resistant metastatic PC currently no curative treatment exists. It has been
suggested that AR expression in PC is modulated by CSCs and the CSC model may be re‐
sponsible for the degree of sensitivity to anti-androgen therapy [114], [115].
The majority of studies to date have focused on the identification of characteristics that po‐
tentially could define CSCs. However, more questions have been raised on the issue which
of these characteristics would be better suited as target and now research has seemed to shift
towards identifying the way these CSCs behave that make them different from bulk tumor
cells. Two important features of acute myeloid leukemia (AML) that allowed to discovery of
new therapeutic agents were CD34+/CD38- and CD33+. Anti-CD33 antibodies have become
an important aspect of CSCs targeted therapy. A drug called Gemtuzumab ozogamacin or
Mylotarg, approved by the FDA in 2000, combines the cytotoxic antibiotic calicheamicin
with the monoclonal anti-CD33 antibody [116].
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Androgen-Independent miRNAs
Up-regulated Down-regulated
miR-184 miR-128b
miR-361 miR-221
miR-424 miR-222
miR-616 miR-146a/b
miR-148a
miR-663
Cancer Stem Cell, Invasion or Metastasis Related miRNAs
Up-regulated Down-regulated
miR-377 miR-34a
miR-141 miR-143
miR-145
miR-15
miR-16
Common Cancer Related miRNAs
Up-regulated Down-regulated
miR-182 miR-125b
miR-96 miR-15a/16-1
miR-375 miR-34a
miR-205
miR-145
miR-221
miR-222
miR-181b
miR-31
miR-200c
Table 2. Up- and down-regulated microRNAs in postate cancer [113]
Novel therapeutic strategies against locally advanced and/or metastatic hormone-refracto‐
ry prostate cancers (HRPCs) by targeting different oncogenic signaling cascade elements
are listed in Table 3. Recent studies have revealed that the blockade of these tumorigenic
signaling cascades could be beneficial as adjuvant therapy in the early phases of PC for
decreasing the risk of  relapse as well  as in the late stages for improving the efficacy of
current  androgen deprivation therapy,  radiotherapy,  and/or  systemic  chemotherapy and
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patient survival rates [117]. Inhibition of the epidermal growth factor (EGFR) pathway by
anti-EGFR antibody or EGFR tyrosine kinase inhibitor causes a cell  cycle arrest,  inhibits
invasion and/ or induces apoptosis in metastatic PC cells when applied in vitro or in vivo
[118-120]. Blockade of the SHH signaling pathway, which is important in stem cell self-re‐
newal, by cyclopamine leads to long-term PC regression without recurrence, strongly sug‐
gesting a connection between this pathway and PCSCs [121].  Salinomycin, a structurally
related compound to monensin, was recently identified as a potent PCSC inhibitor [122].
It inhibited the growth of PCs, but did not affect non-malignant prostate epithelial cells.
That salinomycin impaired PCSC growth and function was evident by the findings of re‐
duced CD44+ cell fraction and ALDH activity. Moreover, salinomycin reduced the expres‐
sion of  MYC, AR and ERG; induced oxidative stress;  and,  inhibited NF-κB activity and
cell migration.
Regulation of the cell cycle is frequently altered in PC, in part, by the interplay of activation
of oncogenic cascades with diverse hormones, growth factors, and cytokines. Thus, inhibi‐
tors of cell cycle regulatory proteins have become an area of increased interest in targeting
CSCs [123]. The cyclin-dependent kinase inhibitor VMY-1-103 inhibited at very low concen‐
trations the Erb-2/Erb-3/heregulin-induced cell proliferation in LNCaP PC cells. [124]. It was
also observed that VMY-1-103 induced apoptosis via decreased mitochondrial membrane
polarity; and induced p53 phosphorylation, caspase-3 activation, and PARP cleavage in
these PC cells, which do express endogen wild type p53. But, VMY-1-103 failed to induce
apoptosis in the p53-null PC cell line PC3 [124]. These results, strongly suggest that
VMY-1-103 may be an effective therapeutic agent, either alone or in combinations with other
drugs, in treating PC.
Adhesion receptors of the integrin family, particularly αv-integrins, have functions including
bone homing by cancer cells, tumor-induced angiogenesis, and osteoclastic bone resorption.
Targeting of integrins by an αv-integrin antagonist (GLPG0187) could inhibit the de novo for‐
mation and progression of bone metastases in PC by antitumor (including inhibition of epi‐
thelial-to-mesenchymal transition and the size of the PCSC population), antiresorptive, and
antiangiogenic mechanisms [125].
Targeting the local microenvironment niche and stromal components of the CSCs would
comprise two other promising therapeutic approaches. For instance, it is known that partic‐
ularly the combined use of antiangiogenic agents with cytotoxic drugs inhibits tumor
growth and invasion. Combining docetaxel with the EGFR-targeting agent cetuximab and
the antiangiogenic agent sunitinib (SUTENT) inhibits tumor growth approximately 50% at
the end of the 3rd week dosing schedule [126]. Targeting the fibroblast-to-myofibroblast tran‐
sition with halofuginone (inhibitor of collagen type I) may also synergize with low doses of
chemotherapy in achieving a significant antitumor effect, avoiding the need of high-dose
chemotherapy and its toxicity without impairing treatment efficacy [57]. These results all
support the idea that targeting PCSCs, their further differentiated progenies, and microen‐
vironment could be more effective to counteract PC transition to invasive and metastatic
stages.
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Target Effect Molecules Reference
EGFR signaling pathway
Anti-EGFR antibody Cetuximab, Erbitux, mAb-C225, IMCC225
[118, 120]
EGFR tyrosine kinase inhibitor Gefinib, Erlotinib,EKB-569
SHH signaling pathway Signaling inhibition
GDC-0449 [127]
Cyclopamine [121]
Anti-SHH antibody [128]
Cell signaling pathway Reducing ALDH activity and CD44
+ cell
fraction
Salinomycin [122]
STAT3 signaling pathwaySTAT3 signaling inhibitor Galiellalactone [78]
WNT/β-Catenin
signaling pathway
Suppression of the WNT co-receptor LRP6
expression
Silibinin [129]
Cell cycle Cyclin-dependent kinase inhibitor VMY-1-103 [124]
Adhesion receptors αv-integrin antagonist GLPG0187 [125]
Niche and stromal
components
Collagen type I inhibitor Halofuginone [57]
Anti-angiogenic agent Sunitinib, SUTENT [126]
Telomerase reverse transcriptase (hTERT)
promoter-induced CXCR4 knockdown
siRNA [130]
Table 3. Novel targets for therapy against advanced prostate cancer
5. Conclusion
Despite all recent developments in cancer diagnosis and therapy, PC still remains one of the
leading causes of cancer related deaths in men. Nevertheless, designed new tools for precise
diagnosis will enable researchers to distinguish patients “who will be recurred earlier, but
will require more extensive treatments” from those “who will have lifespan less effected
from their disease”. Unlike some other solid tumors, PC is one of these tumor types in
which limited treatment options are available so far and gain of drug-resistance is seen more
often. That is why there is an urgent need for alternative and novel therapies.
CSCs are believed to be a subpopulation of cancer cells that modulate malignancy and show
resistance to current anticancer treatments, which make them indicators of poor prognosis.
There are still many aspects of CSCs that remain to be discovered; like, which main mecha‐
nisms regulate normal SC function and how are they used by malignant cells to propagate
the disease? A careful dissection of the main differences between normal adult SCs and
CSCs as well as of their overlapping aspects are important to distinguish how cancers pro‐
ceed. Transforming the gained knowledge in CSC biology into effective therapies would
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then help patients to regain their health much earlier. Altogether, that is the reason why the
relation between the expressed CSC markers and resulting malignant behavior needs to be
sufficiently understood, as they are primarily relevant with the prognosis of cancer.
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